Saitama Medical University International Medical Center Selects MRIdian® MRI-Guided Radiation Therapy System
ViewRay, Inc. (NASDAQ: VRAY) announced the purchase of a MRIdian MRI-Guided Radiation Therapy System by Saitama Medical University International Medical Center for its cancer center in Hidaka-City, Japan. Scheduled for installation in December 2022, the system will enhance personalized treatments for various cancers, including those of the pancreas and prostate. This advanced technology allows for real-time tracking and automated beam gating, facilitating efficient treatment delivery. Saitama aims to participate in international research to further cancer treatment methodologies.
- MRIdian system purchase enhances treatment options for cancer patients.
- Allows for real-time tracking and automated beam gating, improving treatment accuracy.
- Participation in international research could lead to advancements in cancer therapy.
- None.
CLEVELAND, July 19, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that Saitama Medical University International Medical Center has purchased a MRIdian MRI-Guided Radiation Therapy System to complete its newly built comprehensive cancer center in Yamane, Hidaka-City. The MRIdian system will enable Saitama Medical University to offer advanced MRI-guided radiation therapy technology to cancer patients who are seeking personalized treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.
Saitama Medical University International Medical Center is slated to install its MRIdian system in December 2022, with the first patient treatments beginning in early 2023. The center is eager to utilize MRIdian's real-time tracking and automated beam gating technology to support aggressive stereotactic body radiation therapy (SBRT) and treat complex cases. Indications of particular interest to Saitama Medical University researchers are pancreas and prostate, with a desire to participate in multi-centered international research hospital trials.
"Our focus on high-quality medical treatment with an emphasis on patient safety and satisfaction makes MRIdian a perfect addition to our cancer treatment offerings," said Dr. Shingo Kato, Professor, and Director, Department of Radiation Oncology. "The ability to visualize and track the tumor and control the beam in real-time under MRI guidance and adapt the treatment delivery to the unique anatomical and tumor changes within each patient fully supports our patient-centered approach to care and will be of significant benefit to patients throughout the region."
Saitama Medical University International Medical Center was established in April 2007 with the objective of contributing to regional and Japanese medicine, aiming to create an internationally competitive world-class hospital. In February 2015 Saitama Medical University International Medical Center became the first university hospital in Japan to acquire Joint Commission International (JCI) certification, demonstrating its adherence to international quality standards for medical quality and safety. The motto of the Comprehensive Cancer Center is to treat patients with cancer holistically, not treatment of tumor itself.
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy.
Nearly 24,000 patients have been treated with MRIdian. Currently, 53 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/
Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations.
The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration. Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2022, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation, and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
View original content:https://www.prnewswire.com/news-releases/saitama-medical-university-international-medical-center-selects-mridian-mri-guided-radiation-therapy-system-301588817.html
SOURCE ViewRay, Inc.
FAQ
What recent purchase did ViewRay announce related to the MRIdian system?
When is the MRIdian system expected to be installed at Saitama Medical University?
What types of cancer will the MRIdian system help treat?
What are the key features of the MRIdian MRI-Guided Radiation Therapy System?
What is the significance of Saitama Medical University acquiring the MRIdian system?
